The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...

Nuvation has a best-in-class lung cancer drug that could be approved in the US in June. Read why I'm bullish on the stock ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

According to Statifacts, the global clinical trials market size is calculated at USD 126.30 billion in 2025 and is expected to reach around USD 186.09 billion by 2034, growing at a CAGR of 4.4% from ...

Eli Lilly and Company (NYSE: LLY) is one of two pharmaceutical stocks behind the weight loss drug craze that has impacted the ...

"I'm not much of a crier," Hawks football coach Tony Woolfolk said. "But I was so proud and loved those guys so much that I ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

While first-generation glucagon-like peptide-1 receptor agonists have clearly taken the obesity market by storm, generating billions of dollars for Novo Nordisk A/S and Eli Lilly and Co., several ...

Request To Download Free Sample of This Strategic Report @ Highlighted with 99 tables and 79 figures, this 186-page report ?Asia Pacific Clinical Trials Market 2022-2031 by Product Category (Drugs, ...

Request To Download Free Sample of This Strategic Report@ Highlighted with 148 tables and 111 figures, this 241-page report ?Global Clinical Trials Market 2022-2031 by Product Category (Drugs, ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.